The present invention relates to the stable aqueous pharmaceutical compositions of Adalimumab or its biosimilar or its biobetter. More particularly, it relates to the stable aqueous pharmaceutical compositions of Adalimumab essentially free of surfactant. It also relates to the methods of manufacturing the pharmaceutical composition, method of administration and kits containing the same.La présente invention concerne des compositions pharmaceutiques aqueuses stables dAdalimumab, ou de son biosimilaire ou de son biobetter. Elle concerne plus particulièrement des compositions pharmaceutiques aqueuses stables dAdalimumab pratiquement exemptes de surfactant. Linvention concerne également des procédés de fabrication de la composition pharmaceutique, un procédé dadministration, ainsi que des kits les contenant.
